All In Biotech

Drug Trial Radar · NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children

Last checked: Nov 20, 2026Latest source record: Aug 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 6,635 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,635

Actual

Start

Nov 2004

Primary completion

May 2006

Study completion May 2006

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • motavizumab (MEDI-524)Biological

    Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses

  • palivizumabBiological

    Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of RSV Hospitalization (Includes Deaths by RSV)Time frame: Days 0 - 150
  2. Number of Participants Reporting Any Adverse Events (AEs)Time frame: Days 0 - 150
  3. Number of Participants Reporting Any Related AEsTime frame: Days 0 - 150
  4. Number of Participants Reporting Any Serious Adverse Events (SAEs)Time frame: Days 0 - 150
  5. Number of Participants Reporting Any Related SAEsTime frame: Days 0 - 150
  6. Number of Participants Reporting AEs by Highest Severity GradeTime frame: Days 0 - 150
  7. Number of Participants Who Discontinued Study Drug Due to AEsTime frame: Days 0 - 150
  8. Number of Participants Who DiedTime frame: Days 0 - 150
  9. Number of Participants Reporting Changes in Vital Signs From BaselineTime frame: Days 0 - 150

Locations

344 sites in 24 countries. Site status is shown where the registry gives one.

  • University Of Alabama At Birmingham

    Birmingham, Alabama

  • Alabama Neonatal Medicine OC

    Pike Road, Alabama

  • Maricopa Medical Center

    Phoenix, Arizona

  • Central Arkansas Pediatric Clinic, PA

    Benton, Arkansas

  • The Children's Clinic Of Jonesboro, P.A.

    Jonesboro, Arkansas

  • Arkansas Children's Hospital Research Institute

    Little Rock, Arkansas

  • Arkansas Pediatric Clinic

    Little Rock, Arkansas

  • Little Rock Children's Clinic, PA

    Little Rock, Arkansas

  • Miller Children's Hospital

    Long Beach, California

  • Kaiser Permanente Los Angeles

    Los Angeles, California

  • Children's Hospital of Oakland

    Oakland, California

  • Kaiser Permanente Health Care Plan

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • University of California

    San Diego, California

  • Children's Hospital San Diego

    San Diego, California

  • California Pacific Medical Center

    San Francisco, California

  • Santa Clara Valley Medical Center

    San Jose, California

  • Children's Hospital

    Denver, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Pediatric Pulmonology, LLC

    Stamford, Connecticut

  • A. I. Dupont Hospital For Children

    Wilmington, Delaware

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Shands Hospital At The University Of Florida

    Gainesville, Florida

  • The Nemours Children's Clinic

    Jacksonville, Florida

  • University Of Miami Medical Center

    Miami, Florida

  • Nemours Children's Clinic Biomedical Research

    Orlando, Florida

  • Univ. S. Florida Pediatrics Ambulatory Care Center

    Tampa, Florida

  • Emory University School Of Medicine

    Atlanta, Georgia

  • Georgia Pediatric Pulmonology Associates

    Atlanta, Georgia

  • The Medical College Of Georgia

    Augusta, Georgia

  • Kapiolani Medical Center for Woman and Children

    Honolulu, Hawaii

  • University of Illinois at Chicago

    Chicago, Illinois

  • Children's Memorial Hospital

    Chicago, Illinois

  • Advocate Hope Children's Hospital

    Cook, Illinois

  • Lutheran General Children's Hospital

    Park Ridge, Illinois

  • James Whitcomb Riley Hospital for Children

    Indianapolis, Indiana

  • Memorial Hospital of South Bend

    South Bend, Indiana

  • University of Louisville

    Louisville, Kentucky

  • Louisiana State University MidCity Clinic

    Baton Rouge, Louisiana

Showing 40 of 344 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.